Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (214)	6/2/2003 8:19:50 AM
From: Icebrg	Read Replies (2) \| Respond to of 590

>>7:44AM Abgenix trial may be viewed as mixed bag (ABGX) 10.64: Abgenix and partner Amgen (AMGN) announced at ASCO interim results from a phase 2 study of ABX-EGF in advanced colorectal cancer. "ABX-EGF was well tolerated and clearly showed single-agent antitumor activity in patients with metastatic colorectal cancer. The fully human nature of ABX-EGF confers potential benefits with virtually no risk of allergic reactions. These results are certainly encouraging." (Briefing.com note: Although the data can be seen as positive (10% response rate), it might not be as positive as the mkt expected. Some participants were expecting a response rate closer to 15%.)>> Some people expect a lot of precision evidently, in very small trials. Only 40 patients were evaluated.